- Home
- AVIR vs WIA Comparison
AVIR vs WIA Comparison
Compare AVIR & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVIR | WIA |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 197.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVIR | WIA |
|---|---|---|
| Price | $3.15 | $8.24 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 352.8K | 39.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.29% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $7.56 |
| 52 Week High | $4.02 | $8.91 |
Technical Indicators
Market Signals| Indicator | AVIR | WIA |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 40.98 |
| Support Level | $2.99 | $8.19 |
| Resistance Level | $3.23 | $8.29 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 74.55 | 29.17 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.